NIH Considering Trial of COVID-19 Vaccines and Asymptomatic Transmission

US FDA’s Peter Marks says transmission prevention is one of three key missing data points he’d like from Pfizer and BioNTech’s newly authorized vaccine. Another concern is how the vaccine will work is the virus “drifts.”